Listen to “Significant Advancements Achieved in the Fight Against Lung Cancer, We’re Not Done Yet” on Spreaker.
New Campaign Aims to Help Ensure “No One Missed” in Receiving Critical
Biomarker Testing for Most Common Type of Lung Cancer NoOneMissed.org, www.LUNGevity.org
Despite expanded lung cancer screening guidelines, accelerated progress in the treatment of lung cancer and a continued increase in survival rates, lung cancer remains the leading cause of cancer death in the U.S., 2 Almost one-quarter of all cancer deaths are due to lung cancer – more than breast, prostate and colorectal cancers combined.
Due to the complexities of lung cancer, the adoption of personalized medicine is critical to ensuring people receive the right treatment for their specific type of cancer at the right time. However, many people with the most common type of lung cancer—
non-small cell lung cancer (NSCLC) — are not receiving a fully-informed diagnosis due to a lack of comprehensive biomarker testing that can help identify important characteristics about an individual’s cancer and more precisely inform treatment decisions.
LUNGevity Foundation, the nation’s leading lung cancer-focused non-profit, recently launched No One Missed – a new campaign that aims to increase awareness of comprehensive biomarker testing and empower patients and caregivers to discuss testing with their doctor for a fully-informed diagnosis. Comprehensive Biomarker testing can reveal vital information to help identify the appropriate individualized treatment plan for each NSCLC patient.4
Dr. Jorge Gomez, medical director of the solid tumor oncology unit at Mount Sinai Hospital in New York, and Andrea Ferris, President and CEO of Foundation, as they discuss No One Missed and address:
Recent milestones that will help advance lung cancer care
• Nationwide call for every person diagnosed with NSCLC to receive comprehensive biomarker testing
• Vital information gathered through comprehensive biomarker testing and how it can inform treatment decisions
• 3 key steps for every person living with NSCLC and their caregivers: Talk, Test, Treat
Interview is courtesy: AstraZeneca
 US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962–970. doi:10.1001/jama.2021.1117
2 American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021
3American Cancer Society. What Is Lung Cancer? Atlanta: American Cancer Society; 2019
4 Gierman HJ, Goldfarb S, Labrador M, et al. Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. J Clin Oncol. 2019;37(suppl; abstr 1585).
#fight #against #lung #cancer #no #one #missed #noonemissed #jorge #gomez #andrea #ferris #longevity #critical #biomarker #testing #foundation #care #astra #zeneca